{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06333951",
            "orgStudyIdInfo": {
                "id": "20230167"
            },
            "organization": {
                "fullName": "Amgen",
                "class": "INDUSTRY"
            },
            "briefTitle": "AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",
            "officialTitle": "A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)"
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Amgen",
                "class": "INDUSTRY"
            }
        },
        "descriptionModule": {
            "briefSummary": "The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Thoracic Tumors",
                "Non-small Cell Lung Cancer"
            ],
            "keywords": [
                "Oncology",
                "Methylthioadenosine phosphorylase",
                "AMG 193",
                "PRMT5 inhibitor",
                "MTAP",
                "NSCLC"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 orally (PO) and carboplatin, paclitaxel, and pembrolizumab intravenously (IV)",
                    "interventionNames": [
                        "Drug: AMG 193",
                        "Drug: Carboplatin",
                        "Drug: Paclitaxel",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Subprotocol A: NSCLC Arm B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 PO and carboplatin, pemetrexed, and pembrolizumab IV",
                    "interventionNames": [
                        "Drug: AMG 193",
                        "Drug: Carboplatin",
                        "Drug: Pembrolizumab",
                        "Drug: Pemetrexed"
                    ]
                },
                {
                    "label": "Subprotocol A: NSCLC Arm C",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MTAP-deleted NSCLC will receive a combination of AMG 193 PO and pembrolizumab IV",
                    "interventionNames": [
                        "Drug: AMG 193",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Subprotocol B: NSCLC With KRasG12C Mutation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MTAP-deleted NSCLC and KRasG12C mutation will receive a combination of AMG 193 and sotorasib PO",
                    "interventionNames": [
                        "Drug: AMG 193",
                        "Drug: Sotorasib"
                    ]
                },
                {
                    "label": "Subprotocol C: NSCLC With Brain Metastases",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MTAP-deleted NSCLC with brain metastases will receive AMG 193 PO",
                    "interventionNames": [
                        "Drug: AMG 193"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AMG 193",
                    "description": "Administered PO",
                    "armGroupLabels": [
                        "Subprotocol A: NSCLC Arm B",
                        "Subprotocol A: NSCLC Arm C",
                        "Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A",
                        "Subprotocol B: NSCLC With KRasG12C Mutation",
                        "Subprotocol C: NSCLC With Brain Metastases"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "Administered IV",
                    "armGroupLabels": [
                        "Subprotocol A: NSCLC Arm B",
                        "Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Paclitaxel",
                    "description": "Administered IV",
                    "armGroupLabels": [
                        "Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Administered IV",
                    "armGroupLabels": [
                        "Subprotocol A: NSCLC Arm B",
                        "Subprotocol A: NSCLC Arm C",
                        "Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pemetrexed",
                    "description": "Administered IV",
                    "armGroupLabels": [
                        "Subprotocol A: NSCLC Arm B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Sotorasib",
                    "description": "Administered PO",
                    "armGroupLabels": [
                        "Subprotocol B: NSCLC With KRasG12C Mutation"
                    ]
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\nSubprotocol A, B, and C\n\n* Age \u2265 18 years (or \u2265 legal age within the country if it is older than 18 years).\n* Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing.\n* Homozygous MTAP-deletion\n* Able to swallow and retain PO administered study treatment.\n* Disease measurable as defined by RECIST v1.1.\n\nSubprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC.\n\nArm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab):\n\n- Predominantly squamous histology.\n\nArm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab):\n\n- Predominantly non-squamous histology.\n\nArm C (AMG 193 + pembrolizumab):\n\n- PD-L1 positive.\n\nSubprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.\n\nSubprotocol C\n\n* Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases.\n* Brain lesion meeting RANO-BM criteria for measurable disease.\n\nExclusion Criteria\n\nSubprotocol A, B, and C\n\n* Cardiovascular and pulmonary exclusion criteria as defined in the protocol.\n* Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).\n* History of solid organ transplant.\n* Major surgery within 28 days of first dose of AMG 193.\n* Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.\n* Radiation therapy within 28 days of first dose.\n\nSubprotocol A\n\n- Autoimmune disease or immunodeficiency disease as defined in the protocol'",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "100 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amgen Call Center",
                    "role": "CONTACT",
                    "phone": "866-572-6436",
                    "email": "medinfo@amgen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "MD",
                    "affiliation": "Amgen",
                    "role": "STUDY_DIRECTOR"
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "AmgenTrials clinical trials website",
                    "url": "http://www.amgentrials.com"
                }
            ]
        }
    },
    "hasResults": false
}